

CSD/BSE&NSE/RPT/2023-24 May 09, 2023

To
The General Manager
Department of Corporate Services
BSE Limited

25th Floor, P. J. Towers,

Dalal Street, Mumbai - 400 001

To

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVEN

Scrip Code: 530239

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half year ended March 31<sup>st</sup>, 2023.

This is for your information and record.

Thanking you,

Yours faithfully,
For Suven Life Sciences Limited

SHRENIK SONI

Digitally signed by SHRENIK SONI Date: 2023.05.09 16:06:13 +05'30'

Shrenik Soni

Company Secretary

Encl.: as above

## Suven Life Sciences Limited

Disclosure of related party transactions for the period from October'22 to March'23

Rs.In Lakhs

Disclosure of related party transactions for the period from October 22 to March 23																			
SI. N	No	Details of the party (listed ent /subsidiary) entering into the transaction	Details of	ounterparty	Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit	Value of transaction during the reporting period (see Note 6b	In case monies are due to either party as a result of the transaction (see Note 1)		indebtedness is incurred to Details of the loans, inter-corporate deposits, advances or make or give loans, inter-corporate deposits, advances investments									
		Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary		committee (see Note 6a)			Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ intercorporat e deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
1	. S	uven Life Sciences Limited		Suven Neuro Sciences Inc		Wholly Owned Subsidiary	Investment in subsidiary	0	7,368.73										
2	! S	uven Life Sciences Limited		Suven Pharmaceuticals Limited		Control of Key Managerial	Lease rental expenses	10000.00 Per	56.42										
3	S	uven Life Sciences Limited		Suven Pharmaceuticals Limited		Companies under the Control of Key Managerial Personnel	Sale of Services	Financial Year	7.61										
4	l S	iuven Life Sciences Limited		Mrs Sudharani Jasti		Key management personnel	Short term employee benefits	0	52.87										
5	S	uven Life Sciences Limited		Prof. Dr. Seyed E. Hasnain		Key management personnel	Sitting fee	Not Applicable	0.90			_							
6	i s	uven Life Sciences Limited		Mr M Gopalakrishna		Key management personnel	Sitting fee	Not Applicable	1.60										
7	' S	uven Life Sciences Limited		Mrs J.A.S. Padmaja		Key management personnel	Sitting fee	Not Applicable	0.60										
8	S	uven Life Sciences Limited		Mr Santanu Mukherjee		Key management personnel	Sitting fee	Not Applicable	1.50										